Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management.
about
Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse ModelMycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients.Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.Olmesartan-associated enteropathy.Lung transplantation in telomerase mutation carriers with pulmonary fibrosis.Silymarin attenuates mycophenolate mofetil-induced duodenal disorders in ratsGraft-versus-Host Disease-Like Pattern in Mycophenolate Mofetil Related Colon Mucosal Injury: Role of FISH in Establishing the Diagnosis.Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.Mycophenolate mofetil alters the antioxidant status in duodenum of rats: Implication for silymarin usage in mycophenolate mofetil-induced gastrointestinal disorders.Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic reviewEnteric-coated mycophenolate sodium.Effect of mycophenolate mofetil on plasma bioelements in renal transplant recipients.Future immunosuppressive agents in solid-organ transplantation.Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter studyMycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability.A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study.A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients.Not your usual diarrhoea: severe colonic toxicity of mycophenolate due to intestinal CMV and EBV infectionProliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.Drug-induced inflammatory bowel disease and IBD-like conditions.Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors.The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.Iatrogenic pathology of the intestines.The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.Mycophenolate mofetil-induced segmental colitis mimicking ischemic colitis.Mycophenolate mofetil-induced oral ulcerations in solid organ transplant recipients: A report of 3 cases.Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood.Gastrointestinal toxicity of mycophenolate mofetil in rats: Effect of administration time.Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.Correlation of abnormal histology with endoscopic findings among mycophenolate mofetil treated patients.Renal Function and NODM in De Novo Renal Transplant Recipients Treated with Standard and Reduced Levels of Tacrolimus in Combination with EC-MPS.The Immunosuppressant Mycophenolic Acid Alters Nucleotide and Lipid Metabolism in an Intestinal Cell Model.The Effect of Mycophenolate Mofetil on Early Wound Healing in a Rodent Model.Mycophenolate sodium for immunosuppressive treatment in uveitis.Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil.Mycophenolate use in dermatology: a clinical audit.Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.Retrospective evaluation of combined mycophenolate mofetil and prednisone treatment for meningoencephalomyelitis of unknown etiology in dogs: 25 cases (2005-2011).Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.
P2860
Q30386671-D87A2965-E346-4531-BEC6-38C6B9E081ACQ33375192-1D2DB9BB-DE63-4AED-947D-26B8FAB8A81CQ33696568-0DF40F2E-5473-45AC-BCA5-EB9CC845C62FQ33788785-F62D9834-8372-499A-A34B-551686A2D760Q33826806-58BC69CE-1ABA-4E98-B9F7-0403ED20CD13Q33924815-B12BE1B6-6296-45D6-B82C-F35F48684A70Q34336420-4FF7D67A-70F5-43A0-B306-B96FEB284765Q34369032-99BD119A-6B21-48C2-9390-8232786669BCQ34611858-3D445080-F0F0-483E-B042-5045B96D3087Q35035371-A5C0DAEB-6CDB-4055-A515-C41E7D791BB4Q35560664-6C899B2C-1012-49D0-94D3-6C16AFA9134AQ35562618-7EFE8426-CA82-47C8-96C5-63462C4DDF59Q35737431-5EDC3CAF-44FA-4F3C-8503-C2FE4094F8DDQ35841382-66CD6F04-4290-4EB1-B6CC-BA48678112BEQ35891974-35064E38-BEC0-4EF4-9318-8709BB43B6C2Q36544988-496D814C-5355-4F7B-92A8-CCEA2CB9CD4CQ36912373-1CE63E6B-1276-42AD-9EE5-2972777FA00CQ36941933-916ECE34-7FE7-4335-9503-3FC9BA8CAB0EQ37076997-9F308518-4AB6-41EE-99D2-3980B0CFC1AAQ37876951-928529BA-72C1-4B32-80E0-62AB7131D7F1Q38008983-C2B49306-D2CF-45C7-8627-D70FD2B39A60Q38027466-6D6AF1F1-0FCE-404C-873C-51A2BD5CF42FQ38043510-4C08CA1B-84A7-4872-8657-CA5D9A74EDFDQ38339456-9B3F12E7-2897-4EA2-919F-E9067E9C71C6Q38752528-3FA12217-12E0-4997-B560-B2DD5FC020B1Q38964413-6D55A9CC-EB9B-4289-BC3A-47A33DCF1F60Q39552244-717683CB-6753-48A3-A9A7-D0982F181462Q40322745-C0D55370-F3BE-4A21-8786-B87F4B7AF564Q40337822-161BDD42-3375-41D7-850F-3A2DE27F1880Q41107370-FC90EC8B-BB27-4CD0-BD08-4AD6E6035B91Q41477460-2E64FF99-F1F5-4153-AE27-11B2C4FBD98BQ41767570-D845FC11-D10F-4A74-99DA-FF9FCF389B80Q41768816-3E748C84-AAED-4659-BB19-A5A5C7DFAB6BQ42156439-FDD2D5F4-29F7-431B-8E8F-E6105CEA2780Q43225839-231BD207-92ED-4152-8F3F-4B884BE493A8Q46070193-AD60E459-6F97-453D-9F2F-73438BB56950Q46122348-F3272BB9-5275-4BC7-AB76-D8E2B6AE20C9Q46620913-ED81AF23-BA19-4C02-8F23-D8BB0206F28CQ47988727-49FC3DEA-3868-4D9F-B4A1-6E750E763B2AQ50998040-B78FD022-808F-47CE-A851-84C829604B3B
P2860
Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Adverse gastrointestinal effec ...... ogy, incidence and management.
@ast
Adverse gastrointestinal effec ...... ogy, incidence and management.
@en
Adverse gastrointestinal effec ...... ogy, incidence and management.
@nl
type
label
Adverse gastrointestinal effec ...... ogy, incidence and management.
@ast
Adverse gastrointestinal effec ...... ogy, incidence and management.
@en
Adverse gastrointestinal effec ...... ogy, incidence and management.
@nl
prefLabel
Adverse gastrointestinal effec ...... ogy, incidence and management.
@ast
Adverse gastrointestinal effec ...... ogy, incidence and management.
@en
Adverse gastrointestinal effec ...... ogy, incidence and management.
@nl
P1433
P1476
Adverse gastrointestinal effec ...... ogy, incidence and management.
@en
P2093
P304
P356
10.2165/00002018-200124090-00002
P577
2001-01-01T00:00:00Z
P6179
1025769271